JPS631287B2 - - Google Patents
Info
- Publication number
- JPS631287B2 JPS631287B2 JP53043409A JP4340978A JPS631287B2 JP S631287 B2 JPS631287 B2 JP S631287B2 JP 53043409 A JP53043409 A JP 53043409A JP 4340978 A JP4340978 A JP 4340978A JP S631287 B2 JPS631287 B2 JP S631287B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- patients
- treatment
- skin
- azelaic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BDJRBEYXGGNYIS-UHFFFAOYSA-N azelaic acid group Chemical group C(CCCCCCCC(=O)O)(=O)O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 37
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 12
- 208000017520 skin disease Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960004889 salicylic acid Drugs 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 206010040865 Skin hyperpigmentation Diseases 0.000 claims description 4
- 210000000434 stratum corneum Anatomy 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 201000001441 melanoma Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229930003268 Vitamin C Natural products 0.000 description 9
- 235000019154 vitamin C Nutrition 0.000 description 9
- 239000011718 vitamin C Substances 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 150000001991 dicarboxylic acids Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 6
- TVIDDXQYHWJXFK-UHFFFAOYSA-N dodecanedioic acid Chemical compound OC(=O)CCCCCCCCCCC(O)=O TVIDDXQYHWJXFK-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- BNIZTLSGVTUSPW-UHFFFAOYSA-N 2-dodecoxyethanamine Chemical compound CCCCCCCCCCCCOCCN BNIZTLSGVTUSPW-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 229960002242 chlorocresol Drugs 0.000 description 4
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 4
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- DRUKNYVQGHETPO-UHFFFAOYSA-N dimethyl azelate Chemical compound COC(=O)CCCCCCCC(=O)OC DRUKNYVQGHETPO-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 241000384131 Orbicula Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- TWEMKOBYVAMCDD-UHFFFAOYSA-L disodium;dodecanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCCCCCCCCCC([O-])=O TWEMKOBYVAMCDD-UHFFFAOYSA-L 0.000 description 1
- QFYNUCAKHMSPCY-UHFFFAOYSA-L disodium;nonanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCCCCCCC([O-])=O QFYNUCAKHMSPCY-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- DXNCZXXFRKPEPY-UHFFFAOYSA-N tridecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCC(O)=O DXNCZXXFRKPEPY-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯è²çŽ éå€ç®èç
çã®æ²»ççšçµæç©ã«é¢
ããã ç®èè²çŽ éå€çïŒé¡ã®è€è²æã®å Žåã®æ§ã«ãã°
ãã°é¡ãéãããïŒã®æ§ãªç®èç ã¯çŸçåé¡ã°ã
ãã§ãªãæªã æ ¹æ¬çã«è§£æ±ºãããŠããªãæ²»çåé¡
ããããçŸåšè¿ãã€ããããã³ããã³ãã®èªå°äœ
ã®ã¿ãç®èè²çŽ éå€çã®æ²»çã«çäœè©Šéšã§å¹Ÿåå¹
æã瀺ããŠããããããããã¯å¯äœçšãšããŠæã
ãªããåŸãªãé·ææç¶ç軜床çè²åã®çºçããã
ãã ãã®çš®ã®è²çŽ éå€ç®èç ã«ã¯æŽã«é倧ãªç¶æ ã
ãã³çµæããã€ãå±åççºçåç®èç ããã³çè «
æ§ç®èç ïŒé»è²æ§ç¶æ ããã³é»è²è «ã®æ§ãªïŒãšãª
ãããç çåŠçç¶æ ãå«ãŸããããããã®ç®èç
ã«ã¯æªã æå¹ãªå»è¬ãçºèŠãããŠããªãã æ¬çºæã®ç®çã¯äžèšç®çãå³ã¡è²çŽ éå€çã«ã
ãã€ãç®èè²ãæ£åžžãšããŸãççºçåç®èç ãã
ã³çè «æ§ç®èç ãé»æ¢ãæ²»çããã«æçšãªçµæç©
ãæäŸããããšã«ããã æ¬çºæã«ããã°ã掻æ§æåãšããŠå°ãªããšãïŒ
çš®ã®ççŽ ååïŒä¹è³12ããã€ãžã«ã«ãã³é žãåã¯
ãã®è£œè¬äžèš±å®¹ãããå¡©ã補è¬äžèš±å®¹ãããæ äœ
äžã«å«ãããšãç¹åŸŽãšããè²çŽ éå€ç®èç åã¯ç®
èè²çŽ éå€çã®æ²»ççšçµæç©ããæäŸãããã æ¬çºæã§äœ¿çšãããžã«ã«ãã³é žã®å ·äœäŸããã
ãã°ããã¡ãªã³é žãã¹ããªã³é žãã¢ãŒã©ã€ã³é žã
ã»ããã³é žãïŒã»ïŒâããã³ãžã«ã«ãã³é žãïŒã»
10âãã«ã³ãžã«ã«ãã³é žãããã³ïŒã»11âãŠã³ã
ã«ã³ãžã«ã«ãã³é žçã§ããã補è¬äžèš±å®¹ãããå¡©
é¡ã«ã¯ãããªãŠã å¡©é¡ãããã æŽã«å¥œãŸããå®æœæ æ§ã«ããããžã«ã«ãã³é žã¯
ã¢ãŒã©ã€ã³é žã§ããã æ¬çºæã®çµæç©ã¯çµå£æäžãç®äžæ³šå°åã¯ã¯ãª
ãŒã ãè»èãåã¯å¡åžæ¶²ã®åœ¢ã§å±æå¡åžã«ãã€ãŠ
䜿çšåºæ¥ãã æ¬çºæã®çµæç©ã¯ç¹ã«ç«¶åæ©æ§ã«ãã€ãŠããã
ãã·ããŒãŒïŒdopatyrosinaseïŒåå¿ãé»æ¢ããŠç®
èè²çŽ ïŒã¡ã©ãã³ïŒã®çæãæå¶ãããããšãçº
èŠãããããã®äœçšã®æ£ç¢ºãªæ©æ§ã¯æªã§ããã€ãŠ
ããªãããæ¬çºæè ã¯æ¬çµæç©ã®æŽ»æ§æåã«ãã€
ãŠç€ºããããã®ãè¡šããåã¯ããã«é¢ããæ©æ§ã
芳å¯ããã ãããã®èŠ³å¯ã¯æŽã«æ¬çºæã®è«è§£ã«åœ¹ç«ã€ãã
ãããããã®æ©æ§ã®æ±ºå®ç説æãšèããã¹ãã§ã¯
ãªããããŸãã©ããªæå³ã§ãæ¬çºæã®ç¯å²ãéå®
ãããã®ãšèããã¹ãã§ã¯ãªãã ç®èç ã®åå ã§ãããŸãè²çŽ æ¬ ä¹åã¯çœè²ãã°
ããåã¯æç¹ïŒããã€ãªã¢ã·ã¹ ããŒãžã«ã©ãŒïŒ
ã®å€èŠ³ã«ãã€ãŠçŸãããèãããã€ãã¹ãã©ã
ãªãŒãããŠã©ãŒã®äœçšç 究ã«ãããŠè©Šéšç®¡å ãã
ã³çäœå è©Šéšã§è¡ãªã€ã芳å¯ã«ãã€ãŠèãéåžžç®
èäžã«ããçåããã³æ¡æ£ã«å¿ èŠãªèèªé žãå€åœ¢
ããžã«ã«ãã³é žãçæããã®é žã¯åŸã§é»è²âçºç
ã«æå¶å¹æããã€ããšãããã€ãã ãã®ç¹ã§ããååŸè質äŸçµŠãšããŠå·¥åŠçãªã¬ã€
ã³é žãå ããããã€ãã¹ãã©ã ãªãŒãããŠã©ãŒ
å¹é€è©Šéšãããã¡ãªã³é žãã¢ãŒã©ã€ã³é žãããã³
ïŒã»ïŒâããã³ãžã«ã«ãã³é žïŒC11ïŒã®ååšãã¬
ã¹ã¯ãããã°ã©ãæ³ããã³è³ªéåå åæã«ãã確
èªãããããšã¯æ³šç®ãã¹ãã§ãããC9ãšC11å¡ã®
ãžã«ã«ãã³é žãè©Šéšç®¡è©Šéšã§å®è³ªçã«æâããã·
ããŒãŒæŽ»æ§ã瀺ããŠãããããã¯ççŽ ååïŒã10
ããã³12ããã€ãžã«ã«ãã³é žã«ãèŠãããŠããã äžèšãžã«ã«ãã³é žé¡åã¯è£œè¬äžèš±å®¹ãããå¡©é¡
ã¯æ²»çæ³ã«ããçš®ã ã®è£œè¬äžèš±å®¹ããã賊圢å€äž
ã§äœ¿çšåºæ¥ããæ ã«äŸãã°ãããã掻æ§ç©è³ªã®é£
塩溶液äžã®æ³šå°çšæžæ¿æ¶²ã®åœ¢ã§äœ¿çšåºæ¥ããäžæ¹
ããããå±æã«çšããããšãããªãã°ã¯ãªãŒã ã®
圢ã§äœ¿çšåºæ¥ããæŽã«ããããçµå£æäžçšã®åœ¢ã«
ãåºæ¥ãããã®çµæç©ã«å«ãŸãã掻æ§æåéã¯å¹Ÿ
åå€ããããšãåºæ¥ãããžã«ã«ãã³é žåã¯ãã®èª
å°äœã®æ²»çæå¹éãããããšäžããå¿ èŠãªã®ã§ã
ãã æ¬çºæã®çµæç©äžã«å«ãŸãããžã«ã«ãã³é žåã¯
ãããã®è£œè¬äžèš±å®¹ãããå¡©ã®éã¯æçšåœ¢æ ãã
ã³ïŒåã¯ïŒæ²»çæ¡ä»¶ã«ãã€ãŠå€ããæ ã«äŸãã°çµ
å£æäžã®å Žåè¬éã¯æçšåœ¢æ ã®å šéšåã¯å®è³ªçã«
å šéšãæããããã«åãç®äžæ³šå°ã«é©ããæçšåœ¢
æ ã«ãããŠã¯è¬éã¯çµæç©å šééãåºæºãšããŠçŽ
20ä¹è³30ééïŒ ã奜ãŸããã¯çŽ25ééïŒ ã§ããã
çµæç©ã¯å±æ䜿çšã«é©ããã¯ãªãŒã åã¯å¡åžæ¶²ã®
å Žåã¯ãžã«ã«ãã³é žåã¯ãã®èªå°äœã¯çµæç©å šé
éãåºæºãšããŠçŽ10ä¹è³20ééïŒ ã奜ãŸããã¯çŽ
15ééïŒ ã§ããã æ¬çºæã®çµæç©äžã«è§å±€å¥è±å€ãå ãããšãã
ããšãçºèŠãããŠãããããã¯ç¹ã«çµæç©ãç®è
ã«æœçšããããšããå Žåã§ããããã®å Žå䜿çšã
ãè§å±€å¥è±å€ã®äŸãšããŠã¯ãµãªãã«é žããã¿ãã³
ïŒ¡é žã¬ãŸã«ã·ããŒã«ãããšããŒã«ãã¯ã¬ãŸãŒã«ç
ãããã䜿çšã«é©ããè§å±€å¥è±å€ã®éã¯å€ããæ®
éçµæç©å šééã®çŽïŒä¹è³çŽïŒééïŒ ãšããã 掻æ§æåã®è©äŸ¡ æ¬çºæã«ããçµæç©ã®æŽ»æ§ããããã€ãŠå掻æ§
æåã®æŽ»æ§ãè©äŸ¡ããçºè¬çåŠçç 究ããã³çäœ
å è©Šéšãè¡ãªã€ãã ãªã¬ã€ã³é žãå ããæ®éã®åæåªè³ªäžã§20â30
æ¥éæé·ããããããã¹ãã©ã ãªãŒãããŠãŒã©
ïŒçš®4709ïŒå¹é€ã®æ··åè質æœåºæ¶²ïŒçŽ°èããã³
液ããïŒããå®è³ªçã«ããã·ããŒãŒæå¶æŽ»æ§ãã
ã€ããåå¯èœéšåãåŸãããã®éšåãèå±€ã¯ãã
ãã°ã©ãæ³ïŒTLCïŒã«ãããŠããâããã·ããŒ
ãŒåå¿ãæå¶ãããRfïŒ1.3ã®åå¥éšåãåé¢ã
ãã ã¬ã¹ã¯ãããã°ã©ãæ³ãšåŸã®è³ªéåå åæã¯ã
ã®åå¥éšåäžã«å®éçã«ãã¡ãªã³é žãšã¢ãŒã©ã€ã³
é žãäž»äœãšããäžé£ã®C5âC9ãžã«ã«ãã³é žé¡ã®
ååšã瀺ããã çŽé žé¡è©Šæãçšããæ¯èŒè©Šéšããã°ã«ã¿ã«é ž
ïŒC5ïŒã®éšåã®ããã·ããŒãŒæå¶æŽ»æ§ãå šéšé€å€
ããããšã¯å¯èœã§ãã€ããããã®æŽ»æ§ã¯C7å¡ã§
å ã¥æãããšãªãC9ä¹è³C11å¡ã«ãããŠæ倧ãšãª
ãã ç¹ã«é µçŽ 掻ååè©Šéšã¯ã¢ãŒã©ã€ã³é žãKiïŒ
4.10-4Mã§ããã·ããŒãŒã®ç«¶åæå¶å€ã§ããããš
ã瀺ããŠããã 以äžã®å®æœäŸã«ãã€ãŠæ¬çºæãæŽã«å ·äœçã«èª¬
æããããããã®å®æœäŸã«ãããŠåã«ã¢ãŒã©ã€ã³
é žãããã«ã³ãžãªã€ãã¯é žçãšããã¯ã¡ã«ã«ãã
åºããããªããžã«ã«ãã³é žèªäœã§ããã å®æœäŸ ïŒ ãã®å®æœäŸã®æ«å°Ÿã«ç€ºãçµæããã€ã¢ãŒã©ã€ã³
é žå«æã¯ãªãŒã ã次ã®æ£è ã®æè²æç¹ã«30æ¥éïŒ
æ¥ã«ïŒåå¡åžããã (a) è€è²æã«ããã€ã20æ£è (b) ã·ãããïŒCivatteïŒã®å€åœ¢ç®èçã«ããã€
ãïŒæ£è (c) ãããªãŠãŒã€ã«ã®éå±æ§ççºçåé»è²çïŒæª
æ§ãã°ããïŒã«ããã€ã10æ£è æ²»ççµäºæã«(a)ããã³(b)ã®æ£è ã¯ãã¹ãŠè²çŽ é
å€éšåãæããã«æ²»çããã(c)ã®æ£è ã¯ãã¹ãŠçŸ
æ£ã®èšåºçããã³çµç¹åŠçãªè»œæžã瀺ãããïŒå¹Ž
åŸã«èŠ³å¯ããåŠæ²»çæ£è ã«çœæçè·¡ãå šãèªãã
ããªãã€ãã éå±æ§ççºçåé»è²çãççºçåç®èç ã®ç¯ã¡
ããã«å ¥ãããšã¯èŠã®ããããªãã ããããã®æ£
è ã«ãããŠèšåºçæ²»çãåŸãã®ã¿ãªããçµç¹åŠç
æ²»çãåŸãããšã¯æ ¹æ¬çã«éèŠãªããšã§ããã ã¢ãŒã©ã€ã³é ž 15.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ïŒé žåãã¿ã³ 1.0ã ãµãªãã«é ž 2.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ã ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
1.0ã ãªãªãŒãæ²¹ 2.0ééïŒ ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã å®æœäŸ ïŒ æªæ§ã»ããçŸæ£ã®10人ã®æ£è ã«äžèšã®çµæãã
ã€ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ãïŒæ¥ã«ïŒåå±æå¡
åžããŠæ²»çãè¡ã€ãã ã¢ãŒã©ã€ã³é ž 20.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ïŒé žåãã¿ã³ 1.0ã ãµãªãã«é ž 3.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ééïŒ ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
1.0ã ãªãªãŒãæ²¹ 2.0ã ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã çŸæ£ã®å Žæããã³ïŒåã¯å€§ããã«ããããã®å®
æœäŸã®æ²»çãåããªããã°å€ç§çæ²»çãå¿ èŠãšã
ããšããã§ãã€ãæ£è ã®ã¿ãè©ŠéšãããïŒäººã®æ£
è ã«ãããŠãçµç¹åŠçã«ç¢ºèªãããæªæ§ã»ããçŸ
æ£ã®å®å šãªèšåºç軜æžã次ã®å±ææ²»çã«ãã€ãŠé
æãããã ïŒã12ã±æã®æ²»çæéãå¿ èŠã§ãã€ãããå¯ïŒ
人ã®æ£è ã®ã¿ã¯24ã±æã®æ²»çãå¿ èŠãšãããïŒäºº
ã®æ£è ã¯å®å šãªèšåºç軜æžãããããã«ååãªæ
éæ²»çãåããªãã€ããæ²»çéå§åŸãŸããªãã®å°
ããå±æçççåå¿ããã³å ããªããã¶ããå¥ã«
ããã°ããã®æ²»çã¯èªãããã»ã©ã®å¯äœçšãªãã«
ååã«èãããããã®ã§ãã€ããçµç¹ã«æªåœ±é¿ã
åãŒãåå¿ã¯ã©ã®æ£è ã«ã芳å¯ãããªãã€ãã æ²»çã¯ã»ããã®å®å šãªéååŸã«ããããæ²»ççµ
äºåŸ18ã±æã®ããªããŒã¢ããæéäžïŒã±æã«äžåºŠ
ã®å²åã§å®æç蚺å¯ãè¡ã€ããåçºã¯å šãèªãã
ããªãã€ãã å®æœäŸ ïŒ æªæ§ã»ããçŸæ£ã®15人ã®æ£è ãäžèšã®çµæãã
ã€ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ã§æ²»çããã ã¢ãŒã©ã€ã³é ž 15.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ïŒé žåãã¿ã³ 1.0ã ãµãªãã«é ž 2.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ã ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
10.0ã ãªãªãŒãæ²¹ 2.0ã ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã ãã¹ãŠã®æ£è ã«ãããŠãæ£éšã¯é¡ã«ããããã®
圢ã¯äžèŠåã§ã倧ããã¯æ£è ã«ãã€ãŠãŸã¡ãŸã¡ã§
0.5ã15cm2ã®ç¯å²ã«ãã€ããã»ããã®è¡šé¢ã¯å¹³ã
ã§ãããåã¯ããéèµ·ããŠããããããŠç¡¬åããŠ
ããã æ£è ïŒ15人ïŒã®æ£éšã«äžèšçµæã®ã¢ãŒã©ã€ã³é ž
å«æã¯ãªãŒã ãïŒæ¥ã«ïŒåå¡åžããŠæ²»çãè¡ã€
ãããã®æ²»çãæªæ§ã»ãããæ²»çãããŸã§ïŒã14
ã±æéïŒãã®æéã¯æªæ§ã»ããã®çºççšåºŠã«ãã
ïŒã±æãã14ã±æéã®éã§å€ããïŒç¶ããã æ£è 15人ã®ãã¡11人ã¯äžèšæéå ã«å®å šãªæ²»ç
ã芳å¯ããããæ®ãã®ïŒäººã¯å®å šã«æ²»çããåã«
æ²»çããããŠããŸã€ãããåã ã«æºè¶³ãã¹ãçµæ
ãšãããç¶æ ã«ãªã€ãã äžèšã®11人ã®ãã¡ïŒäººã«åçºãèªãããããã®
ææã¯æ²»çäžæ¢åŸïŒã43ã±æã§ãã€ãïŒïŒã±æã®
ã±ãŒã¹ã¯å¥ã®åæã«æ°ããçŸæ£ãçããããã§ã
ãïŒããã®ïŒä»¶ã®åçºã®ãã¹ãŠã«ãããŠãäžèšçµ
æã®ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ãå¡åžããŠæ²»çã
ã€ã¥ãããšãããããããå®å šãªæ²»çãããã
ãã å®æœäŸ ïŒ æªæ§ã»ããçŸæ£ã®ïŒäººã®æ£è ïŒãã®ãã¡ã®ïŒäºº
ã¯æ¢ã«é»è²è «ã®æ®µéã«ãã€ãïŒãäžèšçµæã®ã¢ãŒ
ã©ã€ã³é žå«æã¯ãªãŒã ãæ£éšã«å¡åžããããšã«ã
ã€ãŠæ²»çãããåæã®æ²»çïŒé»æ°ååºãäœæž©æ²»
çãç·ïŒã¯äžæåã§ããããããŠå€ç§çåé€ã¯
æåŠãããã ã¢ãŒã©ã€ã³é ž 20.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ãµãªãã«é ž 4.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ã ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
10.0ã ãªãªãŒãæ²¹ 2.0ã ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã äžèšçµæã®ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ãïŒ 1/2
ãïŒã±æã®æéïŒæ¥ã«ïŒåæ£éšã«å¡åžãããåçŽ
ãªã»ããããã€ïŒäººã®æ£è ã®ãã¡ïŒäººã«ã€ããŠïŒ
ãïŒã±æéæ²»çåŸã«ã»ããã®å®å šãªéåãèªãã
ããããã®éåã¯çµç¹ã®æ€æ»ã«ãã€ãŠãç«èšŒãã
ããïŒäººã®æ£è ã¯ïŒ 1/2ã±æåŸã«æ²»çãç¶ããªã
ã€ããé»è²è «ã®æªæ§ã»ããããã€æ£è ã®å Žåãæ²»
çãïŒã±æç¶ãããšãããæ£éšã®å®å šãªéåã芳
å¯ããããæ²»çåã®çµç¹æ€æ»ã¯æªæ§ã»ããé»è²è «
ïŒã¯ã©ãŒã¯ã»ã¬ãã«ïŒïŒã瀺ããããæ²»çåŸã«ã¯
æ®åãã¿ãæ®ãã®ã¿ã§ãã€ãã å®æœäŸ ïŒ æªæ§é»è²è «ãšèšåºçã«èšºæãããæ£éšããã€23
人ã®æ£è ã«ã€ããŠæ²»çãè¡ã€ããã¯ããã«ãçš®ã
ã®å Žæã«è»¢ç§»ã®ããŸãã¯å±éšãããã¯çµç¹äžã®æ£
éšããã€æãã¯ïŒæ¬¡çŸæ£ããéãæ£éšããã€æ£è
ããããã§å®æœäŸïŒã«èšèŒã®ã¢ãŒã©ã€ã³é žå«æã¯
ãªãŒã ãïŒæ¥ã«ïŒåå¡åžããæ²»çã16é±éç¶ãã
次ãã§ããã€ãã®ã±ãŒã¹ã«ãããŠæ£éšã®åé€ãè¡
ã€ããæåŸã«åç©ã«ã€ããŠã®æ¥æ§ããã³æ ¢æ§ã®æ¯
æ§è©Šéšããã³çªç¶å€ç°ã®è©Šéšãè¡ã€ãåŸã«ãä»ã®
åæ§ã®æ£è ã«æ¯æ¥10ã15ïœã®ã¢ãŒã©ã€ã³é žãäžèš
ã®å±æå¡åžã®å€ã«å æçšã«ãã»ã«ã®åœ¢æ ã§çµå£æ
äžããããã®çæ³ã®æå©ãªå¹æã確èªããåŸã«ã
è¡šé¢äžã«åºãã€ãŠããåã¯ç¯ãäœã€ãŠããäžæ¬¡é»
è²è «ããã¡ãå€ç§æè¡ãåŸ ã€ãŠããæ£è ã«å€ç§æ
è¡ã«ããåé€åã«åæ§ã®å±æå¡åžããã³çµå£æäž
ãïŒã12é±ééè¡ã€ããçµå£æäžã¯æè¡åŸãïŒã±
æéãŸã§ç¶ãããåé€æ£éšãå åŠé¡åŸ®é¡ããã³é»
åé¡åŸ®é¡ã§æ€æ»ããã ãããã®çµæã¯è «çã®çš®é¡ããã³ã¢ãŒã©ã€ã³é ž
ã®æäžæéã«å¿ããŠå€åãããããã¹ãŠã®å Žåã«
ãããã¯åºæ¬çã«ã¯é¡äŒŒããŠããã次ã®ç¹åŸ®ãå«
ãã§ããã æ£éšã®åçžã®æ¡å€§é»æ¢ããã³ããã«ç¶ãæ£éšã®
éåãšå ±ã«çè²ã®çŽ¯é²çæè²åãèªãããããç¯
ãäœã€ãŠããåºåã¯å¯žæ³ãå°ãããªãå¹³ãã«ãªã€
ãŠããããšãèªããããã å®æœäŸ ïŒ ã¢ãŒã©ã€ã³é žåã¯ããã«ã³ãžãªã€ãã¯é žåã¯ã
ããã®å¯Ÿå¿ãããããªãŠã å¡©ãè ¹è å ãç®äžåã¯
çµå£æäžããå Žåã®ããŒãã€ã³ã°âããã»ã€é»è²
è «æå¶å¹æãè©Šéšããçºæ¬¡ã®å®éšãè¡ãªã€ãïŒ ããŒãã€ã³ã°âããã»ã€é»è²è «ã移æ€ãããã
ã¿ïŒãã«ãã¢ã«ããã»ã©ããïŒã«ã¢ãŒã©ã€ã³é ž
ïŒïŒ£âïŒïŒåã¯ããã«ã³ãžãªã€ãã¯é žïŒïŒ£â12ïŒ
åã¯ãããã®å¯Ÿå¿ãããããªãŠã å¡©ãå«ãçµæç©
ãè ¹è å ãç®äžåã¯çµå£æäžããŠæ²»çãããæ²»ç
ã¯åç©ãé»è²è «æ¥çš®ããã24æéåŸã«åããïŒé±
éç¶ããã 䜿çšããæ²»ççšçµæç©ãšãã®æäžæ¹æ³ïŒããã³
æäžéïŒã¯æ¬¡ã®ãšããã§ããããªããå¯Ÿç §ããšã¯
æ²»ççšæåãå«ãŸãªããã©ã³ã¯è©Šéšçšã®çµæç©ã
ããã (a) å¯Ÿç § äžèšã®çµæã®å¡©æº¶æ¶²120ÎŒãæ¯æ¥ïŒåè ¹è
å åã¯ç®äžæ³šå°ããã ãã¿ãã³ïŒ£ 1.0ééïŒ ããŠã€ãŒã³80 2.5ã 塩氎㧠100ïŒ ãšããã (b) C9è ¹è å (1) äžèšçµæã®å¡©æº¶æ¶²120ÎŒãæ¯æ¥ïŒåè ¹è å
泚å°ããã ã¢ãŒã©ã€ã³é ž 1.0ééïŒ ã¢ãŒã©ã€ã³é žãžã¡ãã«ãšã¹ãã« 5.0ééïŒ ãã¿ãã³ïŒ£ 1.0ã ããŠã€ãŒã³80 2.5ã 塩氎㧠100ïŒ ãšããã (c) C9ç®äž(1) äžèš(b)ã®çµæç©ãæ¯æ¥ïŒåç®äžæ³šå°ããã (d) C12ç®äž(1) äžèšçµæã®å¡©æº¶æ¶²120ÎŒãæ¯æ¥ïŒåç®äžæ³š
å°ããã ããã«ã³ãžãªã€ãã¯é ž 1.0ééïŒ ããã«ã³ãžãªã€ãã¯é žãžã¡ãã«ãšã¹ãã« 5.0ã ãã¿ãã³ïŒ£ 1.0ã ããŠã€ãŒã³80 2.5ã 塩氎㧠100ïŒ ãšããã (e) C9çµå£(2) äžèšçµæã®æ°Žæº¶æ¶²ãéæïŒããªãã¡è©Šéšåç©
ã飲ãã«ãŸãããŠïŒçµå£æäžã ã¢ãŒã©ã€ã³é žãããªãŠã å¡© 2.0ééïŒ ãã¿ãã³ïŒ£ 0.1ã æ°Žãå ã㊠100ïŒ ãšããã (f) C12çµå£(2) äžèšçµæã®æ°Žæº¶æ¶²ãéæçµå£æäžã ããã«ã³ãžãªã€ãã¯é žãããªãŠã å¡© 2.0ééïŒ ãã¿ãã³ïŒ£ 0.1ã æ°Žãå ã㊠100ïŒ ãšããã ãããã®è©Šéšçµæã¯åŸèšã®è¡šã«ç€ºããšããã§
ãããè¡šã®ãè©Šéšãã®æ¬ã®ããã³ãªã笊å·
ã¯è©Šéšããåç©ã®æ°ã30ïŒç¬Šå·ïŒã§ãããã15
ïŒç¬Šå·ïŒã§ãããã«ãã€ãŠè©Šéšå 容ãåé¡ãã
ãã®ã§ãããè¡šã®ãæ²»ççšçµæç©ãšãã®æäžæ¹
æ³ïŒããã³æäžéïŒãã®æ¬ã®ãå¯Ÿç §ãããC9è ¹è å
(1)ãããC9ç®äž(1)ãããC12ç®äž(1)ãããC9çµå£(2)
ãã
ãã³ãC12çµå£(2)ãã¯ããããäžèš(a)ã(b)ã(c)ã
(d)ã(e)ããã³(f)ã®å 容ãè¡šãããè¡šã®ãåºçŸ
æ¥ãã¯è©Šéšããããã¿ã«ã€ããŠãæ¥çš®åŸã«è©²ãã
ã¿ã«é»è²è «ãåºçŸããæ¥ãè¡šããã è¡šã®ãïŒé±ååŸã®çµæãã®ãæ»äº¡æ°ãã®æ¬ã®
ïŒè¡ç®ã®ã15ããªãæ°å€ã¯ç°åžžã«é«ãããããã¯
次ã®ïŒã€ã®çç±ã«ããã第ïŒã«ãè ¹è å 泚å°ã¯è©Š
éšåç©ã«å€§ããªã·ãšãã¯ãåãŒãã®ã§ãã·ãšãã¯
ã«åŒ±ãïŒçæ¥ã®æ§è³ªïŒè©Šéšåç©ãæ»ãã ããã§ã
ãã第ïŒã«ãã®ãããªã·ãšãã¯ã«åŒ±ãåç©ã¯äœ¿çš
ã¯ãå¡©æ°Žã«ãèããããªãã€ãã§ããããšæšå®ã
ããããïŒé±ååŸã®çµæãã®ãæ»äº¡æ°ãã®æ¬ã®ïŒ
è¡ç®ã®ãïŒããªãæ°å€ãäžèšã15ãã®æ°å€ããé
åžžã«äœãããããã¯ã·ãšãã¯ã«åŒ±ãåç©ãæ¢ã«æ»
ãã ã®ã§ãæ®åããåç©ïŒã·ãšãã¯ã«åŒ·ãåç©ã®
ã¿ãçãæ®ã€ãïŒã¯ïŒé±ç®ã«å ¥ã€ãŠãæ®ã©æ»ãªãª
ãããã§ããããšæšå®ãããã è¡šã®çµæã¯ããŒãã€ã³ã°âããã»ã€é»è²è «ã
æ¥çš®ããããã¿ïŒãã«ãã¢ã«ããã»ã©ããïŒã«
ã¢ãŒã©ã€ã³é žãããã«ã³ãžãªã€ãã¯é žåã¯ããã
ã®ãããªãŠã å¡©ãè ¹è å ãç®äžåã¯çµå£æäžãã
ããšã«ããè «çã®æé·ãèããé»æ¢ãããããšã
瀺ããŠããã ãªããçµç¹åŠçæ€èšã§æ¬¡ã®ããšãæãããšãªã€
ãã (i) æ²»çããã¿ã®é»è²è «çºéã®åæé 延ã (ii) é»è²è «ã®å€§ããããã³çšåºŠã®æžå°ïŒè¥å¹²ã®æ²»
çããã¿ã«ã€ããŠïŒã (iii) è «çã®ä»£ããã«é»ç®çæïŒé»è²è «ã®å€èŠ³ã®æ¶
æ» ïŒãã®ä»ã®æ²»çããã¿ã«ã€ããŠïŒã (iv) çµç¹æ€æ»ã§èŠåºã ãããæ²»çããã¿ã«ããã
åºç¯ãªå£æ»åã®ååšã ãè¡šã
ããã ç®èè²çŽ éå€çïŒé¡ã®è€è²æã®å Žåã®æ§ã«ãã°
ãã°é¡ãéãããïŒã®æ§ãªç®èç ã¯çŸçåé¡ã°ã
ãã§ãªãæªã æ ¹æ¬çã«è§£æ±ºãããŠããªãæ²»çåé¡
ããããçŸåšè¿ãã€ããããã³ããã³ãã®èªå°äœ
ã®ã¿ãç®èè²çŽ éå€çã®æ²»çã«çäœè©Šéšã§å¹Ÿåå¹
æã瀺ããŠããããããããã¯å¯äœçšãšããŠæã
ãªããåŸãªãé·ææç¶ç軜床çè²åã®çºçããã
ãã ãã®çš®ã®è²çŽ éå€ç®èç ã«ã¯æŽã«é倧ãªç¶æ ã
ãã³çµæããã€ãå±åççºçåç®èç ããã³çè «
æ§ç®èç ïŒé»è²æ§ç¶æ ããã³é»è²è «ã®æ§ãªïŒãšãª
ãããç çåŠçç¶æ ãå«ãŸããããããã®ç®èç
ã«ã¯æªã æå¹ãªå»è¬ãçºèŠãããŠããªãã æ¬çºæã®ç®çã¯äžèšç®çãå³ã¡è²çŽ éå€çã«ã
ãã€ãç®èè²ãæ£åžžãšããŸãççºçåç®èç ãã
ã³çè «æ§ç®èç ãé»æ¢ãæ²»çããã«æçšãªçµæç©
ãæäŸããããšã«ããã æ¬çºæã«ããã°ã掻æ§æåãšããŠå°ãªããšãïŒ
çš®ã®ççŽ ååïŒä¹è³12ããã€ãžã«ã«ãã³é žãåã¯
ãã®è£œè¬äžèš±å®¹ãããå¡©ã補è¬äžèš±å®¹ãããæ äœ
äžã«å«ãããšãç¹åŸŽãšããè²çŽ éå€ç®èç åã¯ç®
èè²çŽ éå€çã®æ²»ççšçµæç©ããæäŸãããã æ¬çºæã§äœ¿çšãããžã«ã«ãã³é žã®å ·äœäŸããã
ãã°ããã¡ãªã³é žãã¹ããªã³é žãã¢ãŒã©ã€ã³é žã
ã»ããã³é žãïŒã»ïŒâããã³ãžã«ã«ãã³é žãïŒã»
10âãã«ã³ãžã«ã«ãã³é žãããã³ïŒã»11âãŠã³ã
ã«ã³ãžã«ã«ãã³é žçã§ããã補è¬äžèš±å®¹ãããå¡©
é¡ã«ã¯ãããªãŠã å¡©é¡ãããã æŽã«å¥œãŸããå®æœæ æ§ã«ããããžã«ã«ãã³é žã¯
ã¢ãŒã©ã€ã³é žã§ããã æ¬çºæã®çµæç©ã¯çµå£æäžãç®äžæ³šå°åã¯ã¯ãª
ãŒã ãè»èãåã¯å¡åžæ¶²ã®åœ¢ã§å±æå¡åžã«ãã€ãŠ
䜿çšåºæ¥ãã æ¬çºæã®çµæç©ã¯ç¹ã«ç«¶åæ©æ§ã«ãã€ãŠããã
ãã·ããŒãŒïŒdopatyrosinaseïŒåå¿ãé»æ¢ããŠç®
èè²çŽ ïŒã¡ã©ãã³ïŒã®çæãæå¶ãããããšãçº
èŠãããããã®äœçšã®æ£ç¢ºãªæ©æ§ã¯æªã§ããã€ãŠ
ããªãããæ¬çºæè ã¯æ¬çµæç©ã®æŽ»æ§æåã«ãã€
ãŠç€ºããããã®ãè¡šããåã¯ããã«é¢ããæ©æ§ã
芳å¯ããã ãããã®èŠ³å¯ã¯æŽã«æ¬çºæã®è«è§£ã«åœ¹ç«ã€ãã
ãããããã®æ©æ§ã®æ±ºå®ç説æãšèããã¹ãã§ã¯
ãªããããŸãã©ããªæå³ã§ãæ¬çºæã®ç¯å²ãéå®
ãããã®ãšèããã¹ãã§ã¯ãªãã ç®èç ã®åå ã§ãããŸãè²çŽ æ¬ ä¹åã¯çœè²ãã°
ããåã¯æç¹ïŒããã€ãªã¢ã·ã¹ ããŒãžã«ã©ãŒïŒ
ã®å€èŠ³ã«ãã€ãŠçŸãããèãããã€ãã¹ãã©ã
ãªãŒãããŠã©ãŒã®äœçšç 究ã«ãããŠè©Šéšç®¡å ãã
ã³çäœå è©Šéšã§è¡ãªã€ã芳å¯ã«ãã€ãŠèãéåžžç®
èäžã«ããçåããã³æ¡æ£ã«å¿ èŠãªèèªé žãå€åœ¢
ããžã«ã«ãã³é žãçæããã®é žã¯åŸã§é»è²âçºç
ã«æå¶å¹æããã€ããšãããã€ãã ãã®ç¹ã§ããååŸè質äŸçµŠãšããŠå·¥åŠçãªã¬ã€
ã³é žãå ããããã€ãã¹ãã©ã ãªãŒãããŠã©ãŒ
å¹é€è©Šéšãããã¡ãªã³é žãã¢ãŒã©ã€ã³é žãããã³
ïŒã»ïŒâããã³ãžã«ã«ãã³é žïŒC11ïŒã®ååšãã¬
ã¹ã¯ãããã°ã©ãæ³ããã³è³ªéåå åæã«ãã確
èªãããããšã¯æ³šç®ãã¹ãã§ãããC9ãšC11å¡ã®
ãžã«ã«ãã³é žãè©Šéšç®¡è©Šéšã§å®è³ªçã«æâããã·
ããŒãŒæŽ»æ§ã瀺ããŠãããããã¯ççŽ ååïŒã10
ããã³12ããã€ãžã«ã«ãã³é žã«ãèŠãããŠããã äžèšãžã«ã«ãã³é žé¡åã¯è£œè¬äžèš±å®¹ãããå¡©é¡
ã¯æ²»çæ³ã«ããçš®ã ã®è£œè¬äžèš±å®¹ããã賊圢å€äž
ã§äœ¿çšåºæ¥ããæ ã«äŸãã°ãããã掻æ§ç©è³ªã®é£
塩溶液äžã®æ³šå°çšæžæ¿æ¶²ã®åœ¢ã§äœ¿çšåºæ¥ããäžæ¹
ããããå±æã«çšããããšãããªãã°ã¯ãªãŒã ã®
圢ã§äœ¿çšåºæ¥ããæŽã«ããããçµå£æäžçšã®åœ¢ã«
ãåºæ¥ãããã®çµæç©ã«å«ãŸãã掻æ§æåéã¯å¹Ÿ
åå€ããããšãåºæ¥ãããžã«ã«ãã³é žåã¯ãã®èª
å°äœã®æ²»çæå¹éãããããšäžããå¿ èŠãªã®ã§ã
ãã æ¬çºæã®çµæç©äžã«å«ãŸãããžã«ã«ãã³é žåã¯
ãããã®è£œè¬äžèš±å®¹ãããå¡©ã®éã¯æçšåœ¢æ ãã
ã³ïŒåã¯ïŒæ²»çæ¡ä»¶ã«ãã€ãŠå€ããæ ã«äŸãã°çµ
å£æäžã®å Žåè¬éã¯æçšåœ¢æ ã®å šéšåã¯å®è³ªçã«
å šéšãæããããã«åãç®äžæ³šå°ã«é©ããæçšåœ¢
æ ã«ãããŠã¯è¬éã¯çµæç©å šééãåºæºãšããŠçŽ
20ä¹è³30ééïŒ ã奜ãŸããã¯çŽ25ééïŒ ã§ããã
çµæç©ã¯å±æ䜿çšã«é©ããã¯ãªãŒã åã¯å¡åžæ¶²ã®
å Žåã¯ãžã«ã«ãã³é žåã¯ãã®èªå°äœã¯çµæç©å šé
éãåºæºãšããŠçŽ10ä¹è³20ééïŒ ã奜ãŸããã¯çŽ
15ééïŒ ã§ããã æ¬çºæã®çµæç©äžã«è§å±€å¥è±å€ãå ãããšãã
ããšãçºèŠãããŠãããããã¯ç¹ã«çµæç©ãç®è
ã«æœçšããããšããå Žåã§ããããã®å Žå䜿çšã
ãè§å±€å¥è±å€ã®äŸãšããŠã¯ãµãªãã«é žããã¿ãã³
ïŒ¡é žã¬ãŸã«ã·ããŒã«ãããšããŒã«ãã¯ã¬ãŸãŒã«ç
ãããã䜿çšã«é©ããè§å±€å¥è±å€ã®éã¯å€ããæ®
éçµæç©å šééã®çŽïŒä¹è³çŽïŒééïŒ ãšããã 掻æ§æåã®è©äŸ¡ æ¬çºæã«ããçµæç©ã®æŽ»æ§ããããã€ãŠå掻æ§
æåã®æŽ»æ§ãè©äŸ¡ããçºè¬çåŠçç 究ããã³çäœ
å è©Šéšãè¡ãªã€ãã ãªã¬ã€ã³é žãå ããæ®éã®åæåªè³ªäžã§20â30
æ¥éæé·ããããããã¹ãã©ã ãªãŒãããŠãŒã©
ïŒçš®4709ïŒå¹é€ã®æ··åè質æœåºæ¶²ïŒçŽ°èããã³
液ããïŒããå®è³ªçã«ããã·ããŒãŒæå¶æŽ»æ§ãã
ã€ããåå¯èœéšåãåŸãããã®éšåãèå±€ã¯ãã
ãã°ã©ãæ³ïŒTLCïŒã«ãããŠããâããã·ããŒ
ãŒåå¿ãæå¶ãããRfïŒ1.3ã®åå¥éšåãåé¢ã
ãã ã¬ã¹ã¯ãããã°ã©ãæ³ãšåŸã®è³ªéåå åæã¯ã
ã®åå¥éšåäžã«å®éçã«ãã¡ãªã³é žãšã¢ãŒã©ã€ã³
é žãäž»äœãšããäžé£ã®C5âC9ãžã«ã«ãã³é žé¡ã®
ååšã瀺ããã çŽé žé¡è©Šæãçšããæ¯èŒè©Šéšããã°ã«ã¿ã«é ž
ïŒC5ïŒã®éšåã®ããã·ããŒãŒæå¶æŽ»æ§ãå šéšé€å€
ããããšã¯å¯èœã§ãã€ããããã®æŽ»æ§ã¯C7å¡ã§
å ã¥æãããšãªãC9ä¹è³C11å¡ã«ãããŠæ倧ãšãª
ãã ç¹ã«é µçŽ 掻ååè©Šéšã¯ã¢ãŒã©ã€ã³é žãKiïŒ
4.10-4Mã§ããã·ããŒãŒã®ç«¶åæå¶å€ã§ããããš
ã瀺ããŠããã 以äžã®å®æœäŸã«ãã€ãŠæ¬çºæãæŽã«å ·äœçã«èª¬
æããããããã®å®æœäŸã«ãããŠåã«ã¢ãŒã©ã€ã³
é žãããã«ã³ãžãªã€ãã¯é žçãšããã¯ã¡ã«ã«ãã
åºããããªããžã«ã«ãã³é žèªäœã§ããã å®æœäŸ ïŒ ãã®å®æœäŸã®æ«å°Ÿã«ç€ºãçµæããã€ã¢ãŒã©ã€ã³
é žå«æã¯ãªãŒã ã次ã®æ£è ã®æè²æç¹ã«30æ¥éïŒ
æ¥ã«ïŒåå¡åžããã (a) è€è²æã«ããã€ã20æ£è (b) ã·ãããïŒCivatteïŒã®å€åœ¢ç®èçã«ããã€
ãïŒæ£è (c) ãããªãŠãŒã€ã«ã®éå±æ§ççºçåé»è²çïŒæª
æ§ãã°ããïŒã«ããã€ã10æ£è æ²»ççµäºæã«(a)ããã³(b)ã®æ£è ã¯ãã¹ãŠè²çŽ é
å€éšåãæããã«æ²»çããã(c)ã®æ£è ã¯ãã¹ãŠçŸ
æ£ã®èšåºçããã³çµç¹åŠçãªè»œæžã瀺ãããïŒå¹Ž
åŸã«èŠ³å¯ããåŠæ²»çæ£è ã«çœæçè·¡ãå šãèªãã
ããªãã€ãã éå±æ§ççºçåé»è²çãççºçåç®èç ã®ç¯ã¡
ããã«å ¥ãããšã¯èŠã®ããããªãã ããããã®æ£
è ã«ãããŠèšåºçæ²»çãåŸãã®ã¿ãªããçµç¹åŠç
æ²»çãåŸãããšã¯æ ¹æ¬çã«éèŠãªããšã§ããã ã¢ãŒã©ã€ã³é ž 15.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ïŒé žåãã¿ã³ 1.0ã ãµãªãã«é ž 2.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ã ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
1.0ã ãªãªãŒãæ²¹ 2.0ééïŒ ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã å®æœäŸ ïŒ æªæ§ã»ããçŸæ£ã®10人ã®æ£è ã«äžèšã®çµæãã
ã€ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ãïŒæ¥ã«ïŒåå±æå¡
åžããŠæ²»çãè¡ã€ãã ã¢ãŒã©ã€ã³é ž 20.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ïŒé žåãã¿ã³ 1.0ã ãµãªãã«é ž 3.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ééïŒ ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
1.0ã ãªãªãŒãæ²¹ 2.0ã ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã çŸæ£ã®å Žæããã³ïŒåã¯å€§ããã«ããããã®å®
æœäŸã®æ²»çãåããªããã°å€ç§çæ²»çãå¿ èŠãšã
ããšããã§ãã€ãæ£è ã®ã¿ãè©ŠéšãããïŒäººã®æ£
è ã«ãããŠãçµç¹åŠçã«ç¢ºèªãããæªæ§ã»ããçŸ
æ£ã®å®å šãªèšåºç軜æžã次ã®å±ææ²»çã«ãã€ãŠé
æãããã ïŒã12ã±æã®æ²»çæéãå¿ èŠã§ãã€ãããå¯ïŒ
人ã®æ£è ã®ã¿ã¯24ã±æã®æ²»çãå¿ èŠãšãããïŒäºº
ã®æ£è ã¯å®å šãªèšåºç軜æžãããããã«ååãªæ
éæ²»çãåããªãã€ããæ²»çéå§åŸãŸããªãã®å°
ããå±æçççåå¿ããã³å ããªããã¶ããå¥ã«
ããã°ããã®æ²»çã¯èªãããã»ã©ã®å¯äœçšãªãã«
ååã«èãããããã®ã§ãã€ããçµç¹ã«æªåœ±é¿ã
åãŒãåå¿ã¯ã©ã®æ£è ã«ã芳å¯ãããªãã€ãã æ²»çã¯ã»ããã®å®å šãªéååŸã«ããããæ²»ççµ
äºåŸ18ã±æã®ããªããŒã¢ããæéäžïŒã±æã«äžåºŠ
ã®å²åã§å®æç蚺å¯ãè¡ã€ããåçºã¯å šãèªãã
ããªãã€ãã å®æœäŸ ïŒ æªæ§ã»ããçŸæ£ã®15人ã®æ£è ãäžèšã®çµæãã
ã€ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ã§æ²»çããã ã¢ãŒã©ã€ã³é ž 15.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ïŒé žåãã¿ã³ 1.0ã ãµãªãã«é ž 2.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ã ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
10.0ã ãªãªãŒãæ²¹ 2.0ã ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã ãã¹ãŠã®æ£è ã«ãããŠãæ£éšã¯é¡ã«ããããã®
圢ã¯äžèŠåã§ã倧ããã¯æ£è ã«ãã€ãŠãŸã¡ãŸã¡ã§
0.5ã15cm2ã®ç¯å²ã«ãã€ããã»ããã®è¡šé¢ã¯å¹³ã
ã§ãããåã¯ããéèµ·ããŠããããããŠç¡¬åããŠ
ããã æ£è ïŒ15人ïŒã®æ£éšã«äžèšçµæã®ã¢ãŒã©ã€ã³é ž
å«æã¯ãªãŒã ãïŒæ¥ã«ïŒåå¡åžããŠæ²»çãè¡ã€
ãããã®æ²»çãæªæ§ã»ãããæ²»çãããŸã§ïŒã14
ã±æéïŒãã®æéã¯æªæ§ã»ããã®çºççšåºŠã«ãã
ïŒã±æãã14ã±æéã®éã§å€ããïŒç¶ããã æ£è 15人ã®ãã¡11人ã¯äžèšæéå ã«å®å šãªæ²»ç
ã芳å¯ããããæ®ãã®ïŒäººã¯å®å šã«æ²»çããåã«
æ²»çããããŠããŸã€ãããåã ã«æºè¶³ãã¹ãçµæ
ãšãããç¶æ ã«ãªã€ãã äžèšã®11人ã®ãã¡ïŒäººã«åçºãèªãããããã®
ææã¯æ²»çäžæ¢åŸïŒã43ã±æã§ãã€ãïŒïŒã±æã®
ã±ãŒã¹ã¯å¥ã®åæã«æ°ããçŸæ£ãçããããã§ã
ãïŒããã®ïŒä»¶ã®åçºã®ãã¹ãŠã«ãããŠãäžèšçµ
æã®ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ãå¡åžããŠæ²»çã
ã€ã¥ãããšãããããããå®å šãªæ²»çãããã
ãã å®æœäŸ ïŒ æªæ§ã»ããçŸæ£ã®ïŒäººã®æ£è ïŒãã®ãã¡ã®ïŒäºº
ã¯æ¢ã«é»è²è «ã®æ®µéã«ãã€ãïŒãäžèšçµæã®ã¢ãŒ
ã©ã€ã³é žå«æã¯ãªãŒã ãæ£éšã«å¡åžããããšã«ã
ã€ãŠæ²»çãããåæã®æ²»çïŒé»æ°ååºãäœæž©æ²»
çãç·ïŒã¯äžæåã§ããããããŠå€ç§çåé€ã¯
æåŠãããã ã¢ãŒã©ã€ã³é ž 20.0ééïŒ ã¯ããã¯ã¬ãŸãŒã« 0.1ã ãµãªãã«é ž 4.0ã ã°ãªã»ããŒã«ã¢ãã¹ãã¢ã¬ãŒã 2.0ã ã»ãã«ã¢ã«ã³ãŒã« 3.0ã ããŠã€ãŒã³80 5.0ã ã©ãŠãªã«ãšãŒãã«ç¡«é žãããªãŠã 10.0ã ãšã¿ããŒã«ã¢ãã³ã©ãŠãªã«ãšãŒãã«ãµã«ããšãŒã
10.0ã ãªãªãŒãæ²¹ 2.0ã ãã¿ãã³ïŒ£ 1.0ã èžç氎㧠100ïŒ ãšããã äžèšçµæã®ã¢ãŒã©ã€ã³é žå«æã¯ãªãŒã ãïŒ 1/2
ãïŒã±æã®æéïŒæ¥ã«ïŒåæ£éšã«å¡åžãããåçŽ
ãªã»ããããã€ïŒäººã®æ£è ã®ãã¡ïŒäººã«ã€ããŠïŒ
ãïŒã±æéæ²»çåŸã«ã»ããã®å®å šãªéåãèªãã
ããããã®éåã¯çµç¹ã®æ€æ»ã«ãã€ãŠãç«èšŒãã
ããïŒäººã®æ£è ã¯ïŒ 1/2ã±æåŸã«æ²»çãç¶ããªã
ã€ããé»è²è «ã®æªæ§ã»ããããã€æ£è ã®å Žåãæ²»
çãïŒã±æç¶ãããšãããæ£éšã®å®å šãªéåã芳
å¯ããããæ²»çåã®çµç¹æ€æ»ã¯æªæ§ã»ããé»è²è «
ïŒã¯ã©ãŒã¯ã»ã¬ãã«ïŒïŒã瀺ããããæ²»çåŸã«ã¯
æ®åãã¿ãæ®ãã®ã¿ã§ãã€ãã å®æœäŸ ïŒ æªæ§é»è²è «ãšèšåºçã«èšºæãããæ£éšããã€23
人ã®æ£è ã«ã€ããŠæ²»çãè¡ã€ããã¯ããã«ãçš®ã
ã®å Žæã«è»¢ç§»ã®ããŸãã¯å±éšãããã¯çµç¹äžã®æ£
éšããã€æãã¯ïŒæ¬¡çŸæ£ããéãæ£éšããã€æ£è
ããããã§å®æœäŸïŒã«èšèŒã®ã¢ãŒã©ã€ã³é žå«æã¯
ãªãŒã ãïŒæ¥ã«ïŒåå¡åžããæ²»çã16é±éç¶ãã
次ãã§ããã€ãã®ã±ãŒã¹ã«ãããŠæ£éšã®åé€ãè¡
ã€ããæåŸã«åç©ã«ã€ããŠã®æ¥æ§ããã³æ ¢æ§ã®æ¯
æ§è©Šéšããã³çªç¶å€ç°ã®è©Šéšãè¡ã€ãåŸã«ãä»ã®
åæ§ã®æ£è ã«æ¯æ¥10ã15ïœã®ã¢ãŒã©ã€ã³é žãäžèš
ã®å±æå¡åžã®å€ã«å æçšã«ãã»ã«ã®åœ¢æ ã§çµå£æ
äžããããã®çæ³ã®æå©ãªå¹æã確èªããåŸã«ã
è¡šé¢äžã«åºãã€ãŠããåã¯ç¯ãäœã€ãŠããäžæ¬¡é»
è²è «ããã¡ãå€ç§æè¡ãåŸ ã€ãŠããæ£è ã«å€ç§æ
è¡ã«ããåé€åã«åæ§ã®å±æå¡åžããã³çµå£æäž
ãïŒã12é±ééè¡ã€ããçµå£æäžã¯æè¡åŸãïŒã±
æéãŸã§ç¶ãããåé€æ£éšãå åŠé¡åŸ®é¡ããã³é»
åé¡åŸ®é¡ã§æ€æ»ããã ãããã®çµæã¯è «çã®çš®é¡ããã³ã¢ãŒã©ã€ã³é ž
ã®æäžæéã«å¿ããŠå€åãããããã¹ãŠã®å Žåã«
ãããã¯åºæ¬çã«ã¯é¡äŒŒããŠããã次ã®ç¹åŸ®ãå«
ãã§ããã æ£éšã®åçžã®æ¡å€§é»æ¢ããã³ããã«ç¶ãæ£éšã®
éåãšå ±ã«çè²ã®çŽ¯é²çæè²åãèªãããããç¯
ãäœã€ãŠããåºåã¯å¯žæ³ãå°ãããªãå¹³ãã«ãªã€
ãŠããããšãèªããããã å®æœäŸ ïŒ ã¢ãŒã©ã€ã³é žåã¯ããã«ã³ãžãªã€ãã¯é žåã¯ã
ããã®å¯Ÿå¿ãããããªãŠã å¡©ãè ¹è å ãç®äžåã¯
çµå£æäžããå Žåã®ããŒãã€ã³ã°âããã»ã€é»è²
è «æå¶å¹æãè©Šéšããçºæ¬¡ã®å®éšãè¡ãªã€ãïŒ ããŒãã€ã³ã°âããã»ã€é»è²è «ã移æ€ãããã
ã¿ïŒãã«ãã¢ã«ããã»ã©ããïŒã«ã¢ãŒã©ã€ã³é ž
ïŒïŒ£âïŒïŒåã¯ããã«ã³ãžãªã€ãã¯é žïŒïŒ£â12ïŒ
åã¯ãããã®å¯Ÿå¿ãããããªãŠã å¡©ãå«ãçµæç©
ãè ¹è å ãç®äžåã¯çµå£æäžããŠæ²»çãããæ²»ç
ã¯åç©ãé»è²è «æ¥çš®ããã24æéåŸã«åããïŒé±
éç¶ããã 䜿çšããæ²»ççšçµæç©ãšãã®æäžæ¹æ³ïŒããã³
æäžéïŒã¯æ¬¡ã®ãšããã§ããããªããå¯Ÿç §ããšã¯
æ²»ççšæåãå«ãŸãªããã©ã³ã¯è©Šéšçšã®çµæç©ã
ããã (a) å¯Ÿç § äžèšã®çµæã®å¡©æº¶æ¶²120ÎŒãæ¯æ¥ïŒåè ¹è
å åã¯ç®äžæ³šå°ããã ãã¿ãã³ïŒ£ 1.0ééïŒ ããŠã€ãŒã³80 2.5ã 塩氎㧠100ïŒ ãšããã (b) C9è ¹è å (1) äžèšçµæã®å¡©æº¶æ¶²120ÎŒãæ¯æ¥ïŒåè ¹è å
泚å°ããã ã¢ãŒã©ã€ã³é ž 1.0ééïŒ ã¢ãŒã©ã€ã³é žãžã¡ãã«ãšã¹ãã« 5.0ééïŒ ãã¿ãã³ïŒ£ 1.0ã ããŠã€ãŒã³80 2.5ã 塩氎㧠100ïŒ ãšããã (c) C9ç®äž(1) äžèš(b)ã®çµæç©ãæ¯æ¥ïŒåç®äžæ³šå°ããã (d) C12ç®äž(1) äžèšçµæã®å¡©æº¶æ¶²120ÎŒãæ¯æ¥ïŒåç®äžæ³š
å°ããã ããã«ã³ãžãªã€ãã¯é ž 1.0ééïŒ ããã«ã³ãžãªã€ãã¯é žãžã¡ãã«ãšã¹ãã« 5.0ã ãã¿ãã³ïŒ£ 1.0ã ããŠã€ãŒã³80 2.5ã 塩氎㧠100ïŒ ãšããã (e) C9çµå£(2) äžèšçµæã®æ°Žæº¶æ¶²ãéæïŒããªãã¡è©Šéšåç©
ã飲ãã«ãŸãããŠïŒçµå£æäžã ã¢ãŒã©ã€ã³é žãããªãŠã å¡© 2.0ééïŒ ãã¿ãã³ïŒ£ 0.1ã æ°Žãå ã㊠100ïŒ ãšããã (f) C12çµå£(2) äžèšçµæã®æ°Žæº¶æ¶²ãéæçµå£æäžã ããã«ã³ãžãªã€ãã¯é žãããªãŠã å¡© 2.0ééïŒ ãã¿ãã³ïŒ£ 0.1ã æ°Žãå ã㊠100ïŒ ãšããã ãããã®è©Šéšçµæã¯åŸèšã®è¡šã«ç€ºããšããã§
ãããè¡šã®ãè©Šéšãã®æ¬ã®ããã³ãªã笊å·
ã¯è©Šéšããåç©ã®æ°ã30ïŒç¬Šå·ïŒã§ãããã15
ïŒç¬Šå·ïŒã§ãããã«ãã€ãŠè©Šéšå 容ãåé¡ãã
ãã®ã§ãããè¡šã®ãæ²»ççšçµæç©ãšãã®æäžæ¹
æ³ïŒããã³æäžéïŒãã®æ¬ã®ãå¯Ÿç §ãããC9è ¹è å
(1)ãããC9ç®äž(1)ãããC12ç®äž(1)ãããC9çµå£(2)
ãã
ãã³ãC12çµå£(2)ãã¯ããããäžèš(a)ã(b)ã(c)ã
(d)ã(e)ããã³(f)ã®å 容ãè¡šãããè¡šã®ãåºçŸ
æ¥ãã¯è©Šéšããããã¿ã«ã€ããŠãæ¥çš®åŸã«è©²ãã
ã¿ã«é»è²è «ãåºçŸããæ¥ãè¡šããã è¡šã®ãïŒé±ååŸã®çµæãã®ãæ»äº¡æ°ãã®æ¬ã®
ïŒè¡ç®ã®ã15ããªãæ°å€ã¯ç°åžžã«é«ãããããã¯
次ã®ïŒã€ã®çç±ã«ããã第ïŒã«ãè ¹è å 泚å°ã¯è©Š
éšåç©ã«å€§ããªã·ãšãã¯ãåãŒãã®ã§ãã·ãšãã¯
ã«åŒ±ãïŒçæ¥ã®æ§è³ªïŒè©Šéšåç©ãæ»ãã ããã§ã
ãã第ïŒã«ãã®ãããªã·ãšãã¯ã«åŒ±ãåç©ã¯äœ¿çš
ã¯ãå¡©æ°Žã«ãèããããªãã€ãã§ããããšæšå®ã
ããããïŒé±ååŸã®çµæãã®ãæ»äº¡æ°ãã®æ¬ã®ïŒ
è¡ç®ã®ãïŒããªãæ°å€ãäžèšã15ãã®æ°å€ããé
åžžã«äœãããããã¯ã·ãšãã¯ã«åŒ±ãåç©ãæ¢ã«æ»
ãã ã®ã§ãæ®åããåç©ïŒã·ãšãã¯ã«åŒ·ãåç©ã®
ã¿ãçãæ®ã€ãïŒã¯ïŒé±ç®ã«å ¥ã€ãŠãæ®ã©æ»ãªãª
ãããã§ããããšæšå®ãããã è¡šã®çµæã¯ããŒãã€ã³ã°âããã»ã€é»è²è «ã
æ¥çš®ããããã¿ïŒãã«ãã¢ã«ããã»ã©ããïŒã«
ã¢ãŒã©ã€ã³é žãããã«ã³ãžãªã€ãã¯é žåã¯ããã
ã®ãããªãŠã å¡©ãè ¹è å ãç®äžåã¯çµå£æäžãã
ããšã«ããè «çã®æé·ãèããé»æ¢ãããããšã
瀺ããŠããã ãªããçµç¹åŠçæ€èšã§æ¬¡ã®ããšãæãããšãªã€
ãã (i) æ²»çããã¿ã®é»è²è «çºéã®åæé 延ã (ii) é»è²è «ã®å€§ããããã³çšåºŠã®æžå°ïŒè¥å¹²ã®æ²»
çããã¿ã«ã€ããŠïŒã (iii) è «çã®ä»£ããã«é»ç®çæïŒé»è²è «ã®å€èŠ³ã®æ¶
æ» ïŒãã®ä»ã®æ²»çããã¿ã«ã€ããŠïŒã (iv) çµç¹æ€æ»ã§èŠåºã ãããæ²»çããã¿ã«ããã
åºç¯ãªå£æ»åã®ååšã ãè¡šã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ æŽ»æ§æåãšããŠå°ãªããšãïŒçš®ã®ççŽ ååïŒ
ä¹è³12ããã€ãžã«ã«ãã³é žåã¯ãã®è£œè¬äžèš±å®¹ã
ããå¡©ã補è¬äžèš±å®¹ãããæ äœäžã«å«ãããšãç¹
城ãšããè²çŽ éå€ç®èç åã¯ç®èè²çŽ éå€çã®æ²»
ççšçµæç©ã ïŒ å±æ䜿çšã«é©ãã圢ã®ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
ã«èšèŒã®çµæç©ã ïŒ ç®èè§å±€å¥è±å€ãå«ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
åã¯ç¬¬ïŒé ã«èšèŒã®çµæç©ã ïŒ ç®èè§å±€å¥è±å€ããµãªãã«é žã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®çµæç©ã ïŒ æ³šå°çšåœ¢æ ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èš
èŒã®çµæç©ã ïŒ çµå£æäžåœ¢æ ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«
èšèŒã®çµæç©ã ïŒ æŽ»æ§æåãã¢ãŒã©ã€ã³é žã§ããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé ä¹è³ç¬¬ïŒé ã®ããããïŒé ã«èšèŒã®çµæ
ç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22617/77A IT1075741B (it) | 1977-04-19 | 1977-04-19 | Composizione per il trattamento di dermatosi iperpigmentarie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53130433A JPS53130433A (en) | 1978-11-14 |
| JPS631287B2 true JPS631287B2 (ja) | 1988-01-12 |
Family
ID=11198481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4340978A Granted JPS53130433A (en) | 1977-04-19 | 1978-04-14 | Composition and method for treating hyperchromocyte skin disease |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS53130433A (ja) |
| AU (1) | AU524602B2 (ja) |
| BE (1) | BE866151A (ja) |
| CA (1) | CA1137873A (ja) |
| CH (1) | CH638099A5 (ja) |
| DE (1) | DE2817133A1 (ja) |
| GB (1) | GB1603563A (ja) |
| IT (1) | IT1075741B (ja) |
| ZA (1) | ZA782125B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8302683D0 (en) * | 1983-02-01 | 1983-03-02 | Unilever Plc | Skin treatment composition |
| JPS61130205A (ja) * | 1984-11-30 | 1986-06-18 | Sunstar Inc | ã¢ã¹ã³ã«ãã³é žãå®å®ã«é åããæ°Žç³»çµæç© |
| US4713394A (en) * | 1986-01-17 | 1987-12-15 | Thornfeldt Carl R | Treatment of nonacne inflammatory and infectious dermatoses and hair loss |
| JP2565513B2 (ja) * | 1987-09-25 | 1996-12-18 | äžç補è¬æ ªåŒäŒç€Ÿ | ã¡ã©ãã³çææå¶å€çšè¬å€ |
| KR910000102A (ko) * | 1988-06-02 | 1991-01-29 | ì ë€ê¹ 믞ìë§ | íšìíì± ìµì ì |
| KR910000101A (ko) * | 1988-06-02 | 1991-01-29 | ì ë€ê¹ 믞ìë§ | íšìíì± ìµì ì |
| DE10039783A1 (de) * | 2000-08-16 | 2002-02-28 | Cognis Deutschland Gmbh | Kosmetische Zubereitungen |
| ITMI20041567A1 (it) * | 2004-07-30 | 2004-10-30 | Maycos Italiana Di Comini Miro | "derivati n-acilati di acidi bicarbossilici con amminoacidi e con idrolizzati proteici vegetali e loro applicazione in prodotti cosmetici, dermofarmaceutici e farmaceutici" |
| DE102006004804A1 (de) | 2006-01-23 | 2007-07-26 | Intendis Gmbh | Verwendung von AlkandicarbonsÀuren und Retinoiden zur Behandlung entzÌndlicher Hauterkrankungen |
| IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
| DE102010021671A1 (de) | 2010-05-27 | 2011-12-01 | Intendis Gmbh | AzelainsÀurehaltige Formulierung mit Pigmentzusatz |
| JP2013170158A (ja) * | 2012-02-22 | 2013-09-02 | Kao Corp | çµå£çŽ«å€ç·æµææ§åäžå€ |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2878237A (en) * | 1955-06-15 | 1959-03-17 | American Cyanamid Co | Mercapto dibasic acids as regulators for the polymerization of acrylic acids, amidesand salts |
-
1977
- 1977-04-19 IT IT22617/77A patent/IT1075741B/it active
-
1978
- 1978-01-01 CH CH690677A patent/CH638099A5/it not_active IP Right Cessation
- 1978-04-12 AU AU35027/78A patent/AU524602B2/en not_active Expired
- 1978-04-13 CA CA000301093A patent/CA1137873A/en not_active Expired
- 1978-04-13 ZA ZA00782125A patent/ZA782125B/xx unknown
- 1978-04-14 JP JP4340978A patent/JPS53130433A/ja active Granted
- 1978-04-18 GB GB15187/78A patent/GB1603563A/en not_active Expired
- 1978-04-19 DE DE19782817133 patent/DE2817133A1/de active Granted
- 1978-04-19 BE BE186928A patent/BE866151A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2817133C2 (ja) | 1988-08-11 |
| JPS53130433A (en) | 1978-11-14 |
| GB1603563A (en) | 1981-11-25 |
| DE2817133A1 (de) | 1978-11-02 |
| AU524602B2 (en) | 1982-09-23 |
| AU3502778A (en) | 1979-10-18 |
| IT1075741B (it) | 1985-04-22 |
| ZA782125B (en) | 1979-03-28 |
| CA1137873A (en) | 1982-12-21 |
| CH638099A5 (en) | 1983-09-15 |
| BE866151A (fr) | 1978-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2454997C2 (ru) | ÐеÑеМОе бПлезМеММÑÑ ÑПÑÑПÑМОй О забПлеваМОй ÑелПвека Ñ ÐžÑпПлÑзПваМОеЌ аМалПгПв О пÑПОзвПЎМÑÑ Ð²ÐžÑаЌОМа к | |
| US6673843B2 (en) | Curcumin and curcuminoid inhibition of angiogenesis | |
| Milman et al. | Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study | |
| Oliveira et al. | Treatment of keloids and hypertrophic scars. Position statement of the Brazilian expert group GREMCIQ | |
| JPS60100517A (ja) | æŸå°ç·æœ°çæ²»çå€ããã³æ¹æ³ | |
| JPS63502437A (ja) | é žçŽ åã³ã¬ã¹ããâã«å«æçµæç©ããã³çŸæ£ã®å±æçåŠçœ®ã®ããã®ãã®çšé | |
| JPH0552814B2 (ja) | ||
| JPS631287B2 (ja) | ||
| JPH07501339A (ja) | åµå·æ²»ççµæç©ïŒãã®èª¿è£œæ¹æ³ãšäœ¿çš | |
| JP4044611B2 (ja) | ããã¹ã¿ã°ã©ã³ãžã³ã®æ°ããªäœ¿çš | |
| MX9206309A (es) | Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa. | |
| Li et al. | Advances in photodynamic therapy of pathologic scar | |
| JPH07300412A (ja) | 掻æ§é žçŽ æ¶å»å€åã³ãããå«ãçµæç© | |
| FRY et al. | Effect of Eetinoic acid in psoriasis | |
| JPH04500824A (ja) | å èåã®äœçšãå埩ãããããã®ç®èã®æ²»çæ¹æ³ | |
| Orfanos et al. | Current developments of oral retinoid therapy with three generations of drugs | |
| US20080274094A1 (en) | Molecular Complex Comprising Arbutine, Ascorbic Acid, Oleuropeina or Its Derivatives Thereof and Related Uses In Medical Field | |
| US7060729B2 (en) | Composition and method for treating skin | |
| US7442690B2 (en) | Topical treatment for psoriasis | |
| GB2562991A (en) | 4-N butylresorcinol in a skincare formulation in concentrations of twenty percent, up to and including sixty percent | |
| JP7291079B2 (ja) | ïœïœã®çç¶ã軜æžããæ¹æ³ | |
| US11590211B2 (en) | Systems for treating dermal inflammatory conditions | |
| US20130202540A1 (en) | Method for repair of acute and chronic injury, such as burned and photodamaged skin | |
| US4818768A (en) | Process for the treatment of hyperpigmentary dermatoses including malignant melanomas | |
| US20070042976A1 (en) | Method of treating cosmetic and dermatologic conditions by a demethylating agent |